EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and Outcomes

Diamantis I Tsilimigras, Hunter Stecko, Dimitrios Moris, Timothy M Pawlik

Journal of Surgical Oncology · 2025-06 · 131 (7) · 1352-1361

DOI: 10.1002/jso.28081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 13.01.2025. Verfasst von Diamantis I Tsilimigras und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus…. Hauptthemen laut MEDLINE: Mutation, Biliary Tract Neoplasms, Biomarkers, Tumor, Cholangiocarcinoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biliary tract cancers (BTCs) represent distinct biological and genomic entities. Anatomic and geographic heterogeneity in genomic profiling of BTC subtypes, genomic co‐alterations, and their impact on long‐term outcomes are not well defined.

Methods

Genomic data to characterize alterations among patients with BTCs were derived from the AACR GENIE registry (v15.1) and other genomic data sets. Patterns of mutational co‐occurrence, frequency of co‐alterations, and their impact on long‐term outcomes among BTC patients were examined.

Results

Alterations in IDH1 and FGFR2 genes were mostly noted among intrahepatic cholangiocarcinoma (iCCA) samples, TP53 , ERBB2/HER2 , and SMAD4 mutations were more frequent among gallbladder cancer (GBC) samples while extrahepatic cholangiocarcinoma (eCCA) more commonly harbored KRAS mutations (all Q < 0.001). Alterations in IDH1 and FGFR2 genes were more frequent among iCCA samples from Western vs. Eastern populations, while KRAS , SMAD4 , and ERBB2 mutations were more commonly observed among Eastern populations(all Q < 0.05). FGFR2 gene was frequently co‐mutated with BAP1 (log2OR: 1.55, Q < 0.001), while IDH1 gene was commonly co‐mutated with PBRM1 (log2OR: 1.09, Q < 0.001). Co‐alteration rate among patients with IDH1 ‐mutant iCCAs, FGFR2 ‐rearranged iCCAs, KRAS ‐mutant eCCA, and HER2 ‐mutant GBCs were 80.8%, 85.2%, 76.7%, and 100%, respectively. Among patients with iCCA and FGFR2 fusions/rearrangements, harboring co‐alterations in the TP53 pathway or PI3K pathway correlated with worse overall survival (OS), while patients with IDH1 ‐mutant iCCA had worse OS when harboring co‐alterations in the cell cycle pathway.

Conclusions

Marked genomic heterogeneity exists among patients with BTCs based on anatomic and geographic location. The overwhelming majority of BTC patients with clinically significant mutations had concurrent genomic co‐alterations. The current study highlights the molecular complexity of BTCs with multiple alterations that commonly co‐exist and could potentially be targeted to treat BTCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationBiliary Tract NeoplasmsBiomarkers, TumorCholangiocarcinomaHumansMaleFemaleMiddle AgedAgedIsocitrate DehydrogenaseReceptor, Fibroblast Growth Factor, Type 2PrognosisSmad4 ProteinGenomics

Stichwörter der Autor:innen

BTCbiliarycholangiocarcinomaco‐mutationsgallbladder cancergenomic profilingnext‐generation sequencing

Substanzen

Biomarkers, TumorFGFR2 protein, humanIsocitrate DehydrogenaseReceptor, Fibroblast Growth Factor, Type 2IDH1 protein, humanSmad4 Protein

Autor:innen und Institutionen

  • Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Department of Surgery, Duke University Hospital, Duke University, Durham, North Carolina, USA.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Tsilimigras, D. I., Stecko, H., Moris, D., & Pawlik, T. M. (2025). Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and Outcomes. Journal of Surgical Oncology, 131(7), 1352-1361. https://doi.org/10.1002/jso.28081

Vancouver

Tsilimigras DI, Stecko H, Moris D, Pawlik TM. Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and Outcomes. Journal of Surgical Oncology. 2025;131(7):1352-1361. doi:10.1002/jso.28081

BibTeX
@article{Tsilimigras2025,
  author = {Tsilimigras, Diamantis I and Stecko, Hunter and Moris, Dimitrios and Pawlik, Timothy M},
  title = {Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and Outcomes},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  volume = {131},
  number = {7},
  pages = {1352--1361},
  doi = {10.1002/jso.28081}
}
Kostenlos starten →